Organon Q3 Revenue Slips 2% to $1.57B as Sun Pharma $14.00 Deal Nears Early-2027 Close
OGN has more than doubled off its 52-week low of $5.69.
Summary
Organon reported Q3 revenue of $1.57 billion, down 2%, and net income of $164 million, while the $14.00-per-share Sun Pharma buyout remains on track to close by early 2027 after stockholder approval.
Key Events · Earnings and Guidance · OGN
-
Q3 Revenue Down 2% to $1.57B
Worldwide sales were $1,574 million versus $1,602 million a year earlier. Nexplanon fell 10% to $200 million on delayed reinsertions and federal funding uncertainty, partly offset by Hadlima up 35% to $86 million.
-
Net Income Flat at $164M
Diluted EPS was $0.60 versus $0.61. Nine-month operating cash flow rose to $702 million from $559 million, and cash and equivalents reached $1,455 million versus $574 million at year-end 2025.
-
Sun Pharma Deal Targets Early 2027
The $14.00-per-share all-cash acquisition received stockholder approval on July 23, 2026. Remaining conditions are regulatory approvals, with closing expected by early 2027.
-
Vtama Patent Challenges Mount
Organon sued Encube, Mylan, Natco and Dr. Reddy's in August-September 2026 over ANDAs for generic Vtama, triggering up to 30-month regulatory stays.
Analysis · OGN · Life Sciences
The pending $14.00-per-share all-cash Sun Pharma acquisition is the main driver for the stock, having cleared stockholder approval and targeting a close by early 2027, so operating results matter chiefly as a check that deal terms hold. Against that backdrop, Q3 revenue fell 2% to $1.57 billion and net income was roughly flat at $164 million, with Nexplanon down 10% on delayed reinsertions and federal funding uncertainty. Cash rose to $1.46 billion on Jada divestiture proceeds, and the company remains in compliance with debt covenants.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 30.6% of the 1568 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OGN was trading at $13.83 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $5.69 to $13.83. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.